Navigation Links
Axxess Pharma Inc. Receives Upgraded Listing on OTCMarkets.com
Date:6/4/2013

MARKHAM, Ontario, June 4, 2013 /PRNewswire/ -- Axxess Pharma Inc. (OTC Pink: AXXE), a pharmaceutical company specializing in the marketing and distribution of both prescription and non-prescription medical products, is pleased to announce the Company is now current in their filings on OTCMarkets.com. The Company is now listed on the OTC Markets website as "Current Information" status. This upgraded listing is expected to increase transparency and investor confidence.

Dr. Daniel Bagi , CEO of Axxess Pharma, Inc. stated, "We are pleased to have accomplished this task for our shareholders.  We remain focused on complete transparency and generating revenues by the second half of 2013. As the weeks and months progress, we will continue to release news regarding product licensing, product distribution, revenues, and brand marketing." Dr. Bagi further stated, "During the last 15 months, the company has worked diligently to bolster management, and initiate revenues and profits through our prescription drugs and over-the-counter nutritional supplements."

For more information, please visit www.axxesspharmainc.com, or contact the Company at (416) 410-6006.

About Axxess Pharma, Inc.:

Axxess Pharma Inc. is a Nevada Corporation operating through its wholly-owned Canadian Subsidiary: Axxess Pharma Canada Inc., headquartered in Toronto.  Axxess is a specialty Health Care Products Company dedicated to improving health and quality of life by offering select medicines, nutritional supplements and over the counter remedies all across the Americas. Axxess's goal is to bring additional products to the market and provide new, innovative options for better health spanning areas such as high cholesterol, blood pressure, acute pain, - to optimal health management through improved nutritional supplements.

Safe Harbor Statement:

Statements about the Company's future expectations and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby.

The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management, as well as assumptions made by any information currently available to the Company or its management. When used in this document, the words "anticipate," "estimate," "expect," "intend," "plans," "projects," and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. Such statements reflect the current view of the Company regarding future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties noted. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove to be incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, expected, intended or projected. In each instance, forward-looking information should be considered in light of the accompanying meaningful cautionary statements herein. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, the impact of competitive services and pricing and general economic risks and uncertainties.

 Contact:

    Axxess Pharma, Inc.
    Daniel Bagi , M.D., CEO
    Phone Number (416) 410-6006
    danielb@axxesspharmainc.com   
    www.axxesspharmainc.com


'/>"/>
SOURCE Axxess Pharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Merrimack Pharmaceuticals Phase 1 Research Supports MM-121 Potential For Investigation As Combination With Chemotherapy In Patients With Advanced Solid Tumors
2. Neues vorfüllbares Spritzensystem bietet hochmoderne Glastechnologie für die Verabreichung injizierbarer biopharmazeutischer Medikamente
3. Pharmacy Technicians Can Be Leaders In Pharmacy Crime Preparedness
4. Array BioPharma Announces Proposed Public Offering of Convertible Debt
5. Craneware Showcases Pharmacy Innovation at ASHP Summer Conference
6. Isis Pharmaceuticals Reports Encouraging Data on ISIS-STAT3rx in Patients With Cancer
7. Chinese Pharmaceutical Market 2013-2023
8. New Book by Entrepreneur and Managed Care Pharmacy Authority Details Her Path to Leadership
9. Ferring Pharmaceuticals Inc. Announces $1M Donation to the Alliance for Fertility Preservation, a Newly Formed Charitable Organization
10. TransCelerate BioPharma Inc. Reveals Collaborative Methodology for Risk-Based Monitoring of Clinical Trials
11. New Prefillable Syringe System Offers Advanced Glass Technology for Biopharmaceutical Injectable Drug Delivery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... -- Eli Lilly and Company (NYSE: LLY ) ... of 2017 on Tuesday, October 24, 2017. Lilly will ... the investment community and media to further detail the ... begin at 9 a.m. Eastern time. Investors, media and ... the conference call through a link that will be ...
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host ... webcast on Friday, November 3, 2017, beginning at 7:00 ... approximately 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... performance and guidance for 2018, Hill-Rom executives will also ... performance, and long-range financial outlook through 2020. ...
(Date:9/25/2017)... , Sept. 25, 2017   Montrium ... Master File solutions, today—from the IQPC Trial Master ... , NL)—announced that EastHORN Clinical Services has ... clinical programs and TMF management. EastHORN, a leading ... eTMF platform to increase transparency to enable greater ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released a ... books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture of ... have tossed it off as mere rubbish, but Yisrayl Hawkins says that is because ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of ... Philippines. “The Journey: From the Mountains to the Mission Field” is the creation of ... taught all ages and currently teaches a class of ladies at her church, which ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... now treating sleep apnea using cutting-edge Oventus O2Vent technology. As many ... sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer significant ...
(Date:10/12/2017)... ... 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the ... new design of the shoulder pad. The shoulder pad provides optimal support and ... pain while using cold therapy. By utilizing ice and water that is circulated from ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
Breaking Medicine News(10 mins):